-
公开(公告)号:US11932675B2
公开(公告)日:2024-03-19
申请号:US17067508
申请日:2020-10-09
申请人: Genentech, Inc. , Xencor, Inc.
发明人: John Desjarlais , Matthew Bernett , Michael Hedvat , Rajat Varma , Suzanne Schubbert , Christine Bonzon , Rumana Rashid , Juan Diaz , Patrick Holder , Christine Huang
CPC分类号: C07K14/5443 , A61P35/00 , C07K16/2818 , A61K38/00 , C07K2319/30
摘要: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
-
2.
公开(公告)号:US20240026002A1
公开(公告)日:2024-01-25
申请号:US18452395
申请日:2023-08-18
申请人: Xencor, Inc.
CPC分类号: C07K16/2818 , A61P35/00 , A61P37/06 , C07K16/2803 , C07K16/2827 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/52 , C07K2317/33 , C07K2317/31 , A61K2039/507
摘要: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
-
公开(公告)号:US20230220081A1
公开(公告)日:2023-07-13
申请号:US18065462
申请日:2022-12-13
申请人: Xencor, Inc.
CPC分类号: C07K16/2818 , C07K14/5443 , C07K14/7155 , C12N15/63 , A61P35/00 , C07K2317/24 , C07K2317/524 , A61K2039/505 , C07K2317/94 , C07K2319/30 , C07K2317/73 , C07K2317/526 , C07K2317/35 , C07K2317/92 , C07K2317/31 , C07K2317/53 , C07K2317/565 , C07K2317/55 , C07K2317/622 , C07K2317/74 , A61K38/00 , C07K2319/32
摘要: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
-
公开(公告)号:US20220380462A1
公开(公告)日:2022-12-01
申请号:US17339774
申请日:2021-06-04
申请人: Xencor, Inc.
发明人: Gregory Moore , Matthew Bernett , Rumana Rashid , John Desjarlais
IPC分类号: C07K16/28
摘要: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
-
公开(公告)号:US11319355B2
公开(公告)日:2022-05-03
申请号:US16206849
申请日:2018-11-30
申请人: Xencor, Inc.
发明人: Matthew Bernett , John Desjarlais , Rajat Varma , Rumana Rashid
IPC分类号: C07K14/55 , C07K14/735 , C12N15/85 , A61K38/00
摘要: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
-
公开(公告)号:US11225528B2
公开(公告)日:2022-01-18
申请号:US16354058
申请日:2019-03-14
申请人: Xencor, Inc.
发明人: Matthew J. Bernett , Gregory Moore , John Desjarlais , Seung Chu , Rumana Rashid , Umesh Muchhal , Sung-Hyung Lee
摘要: The present invention is directed to novel heterodimeric antibodies.
-
公开(公告)号:US11111315B2
公开(公告)日:2021-09-07
申请号:US15945681
申请日:2018-04-04
申请人: Xencor, Inc.
发明人: Matthew J. Bernett , Gregory Moore , John Desjarlais , Seung Chu , Rumana Rashid , Umesh Muchhal , Sung-Hyung Lee
摘要: The present invention is directed to novel heterodimeric antibodies.
-
公开(公告)号:US20210163627A1
公开(公告)日:2021-06-03
申请号:US16918922
申请日:2020-07-01
申请人: Xencor, Inc.
发明人: Gregory Moore , Matthew Bernett , Rumana Rashid , John Desjarlais
摘要: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
-
公开(公告)号:US10982006B2
公开(公告)日:2021-04-20
申请号:US16375777
申请日:2019-04-04
申请人: Xencor, Inc.
发明人: John Desjarlais , Alex Nisthal , Seung Chu
摘要: The present invention relates to novel antigen binding domains and heterodimeric antibodies that bind Fibroblast Activation Protein (FAP).
-
公开(公告)号:US10752678B2
公开(公告)日:2020-08-25
申请号:US15943192
申请日:2018-04-02
申请人: Allergan, Inc. , Xencor, Inc.
发明人: Peter C. Baciu , Yanbin Liang , Jason Guu , Matthew Bernett , Umesh Muchhal , John Desjarlais
IPC分类号: C07K16/18 , A61K39/395 , A61K39/00
摘要: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
-
-
-
-
-
-
-
-
-